Sign In
Buy MRNA
$47.44
-4.15 (-8.04%)
At Close: Jun 05, 2026
Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
06:30am, Monday, 10'th Jun 2024
mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an enhanced i
Why Moderna Stock Is a No-Brainer Buy Right Now
05:50am, Monday, 10'th Jun 2024
Moderna is at an inflection point with the recent FDA approval of its RSV vaccine. The company could have more new products on the way with its promising late-stage pipeline.
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA). In
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
12:00am, Sunday, 09'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ:MRNA). Such investors are advised to conta
3 Reasons to Buy Moderna Stock
06:45am, Saturday, 08'th Jun 2024
Moderna finally earned approval for a non-coronavirus vaccine. The company's cancer vaccine candidate looks very promising.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA
03:03pm, Friday, 07'th Jun 2024
NEW YORK , June 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ: MRNA). Such investors are advised to contac
NEW YORK, NY / ACCESSWIRE / June 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA). In
Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
10:30am, Friday, 07'th Jun 2024
Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending regulatory approval CAMBRIDGE, MA / ACCESSWIRE / June 7, 2024 / Moderna, I
Should You Pick Moderna Stock At $150 After 25% Gains In A Month?
08:45am, Friday, 07'th Jun 2024
The stock price of Moderna has seen a sharp 27% rise in a month, while its peer – BioNTech – has seen its stock rise 10% over this period. Moderna has a couple of factors to back its strong run.
Moderna, Inc. (MRNA) Jefferies 2024 Global Healthcare Conference (Transcript)
08:46pm, Thursday, 06'th Jun 2024
Moderna, Inc. (NASDAQ:MRNA ) Jefferies 2024 Global Healthcare Conference June 6, 2024 10:00 AM ET Company Participants Jamey Mock - CFO Conference Call Participants Michael Yee - Jefferies Michael Yee
5 Stocks Propelling S&P 500 to 25th Record High
11:26am, Thursday, 06'th Jun 2024
The S&P 500 touches a record high for the 25th time this year, powered by technology stocks. We have highlighted five technology stocks, HPE, MRNA, AVGO, MU and LRCX, leading the way higher in the lat
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
11:00am, Thursday, 06'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA). Inv
Center for Biologics Evaluation and Research has chosen mRNA-3705 as one of four investigational medicines for accelerated development to address unmet medical needs for rare diseases CAMBRIDGE, MA /
FDA advisers urge targeting JN.1 strain in fall's COVID vaccines
07:46pm, Wednesday, 05'th Jun 2024
WASHINGTON — Government advisers Wednesday said it's time to update the recipe for the COVID-19 vaccines Americans will receive in the fall — targeting a version of the ever-evolving coronavirus c
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
05:37pm, Wednesday, 05'th Jun 2024
The biotech sector has been through a lot in the past five years and it is finally rebounding. One of the most important sectors globally, it is hard to imagine life without biotech companies that pro
